Synergistic antitumor activity of capecitabine in combination with irinotecan

Clinical Colorectal Cancer

Volumn 4, Issue 5, 2005, Pages 336-343

  Cao, Shousong ^a   Durrani, Farukh A ^a   Rustum, Youcef M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

5 fluorouracil; Combination therapy; p53; Raltitrexed; Synergistic interaction; Xenograft

Indexed keywords

CAPECITABINE; FLUOROURACIL; IRINOTECAN; RALTITREXED;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SELECTIVITY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; LETHALITY; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MOUSE; NONHUMAN; NUDE MOUSE; SQUAMOUS CELL CARCINOMA; TOXICITY TESTING; TUMOR XENOGRAFT; WEIGHT REDUCTION;

EID: 14644399903     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2005.n.007     Document Type: Article

References (35)

1. Pinedo HM, Peters GJ. 5-Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988, 6:1653-1664.
2. Hughes RS, Frenkel E. The role of chemotherapy in head and neck cancer. Am J Clin Oncol 1997; 20:449-461.
3. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992; 10:896-903.
4. Rustum YM, Cao S, Zhang Z. Rationale for treatment design: biochemical modulation of 5-fluorouracil by leucovorin. Cancer J Sci Am 1998; 4:12-18.
5. Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987; 5:1559-1565.
6. Petrelli N, Douglass HOJ, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 1989; 7:1419-1426.
7. Poon MA, O'Connell MJ, Weiand HS, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9:1967-1972.
8. Cao S, Frank C, Shirasaka T, Rustum YM. 5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer. Clin Cancer Res 1995; 1:839-845.
9. Malik STA, Talbot D, Clarke PI, et al. Phase II trial of UFT in advanced colorectal and gastric cancer. Br J Cancer 1992; 62:1023-1025.
10. Douillard JY, Hoff PM, Skillings JR, et al. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002; 20:3605-3616.
11. Shirasaka T, Nakano K, Takechi T, et al. Antitumor activity of I M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996; 56:2602-2606.
12. Cao S, Lu K, Toth K, et al. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-Fluorouracil prodrug in a colorectal tumor model. Clin Cancer Res 1999; 5:267-274.
13. Cohen ST, Leichman CG, Yeslow G, et al. Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin Cancer Res 2002; 8:2116-2122.
14. Ishikawa T, Utoh M, Sawada N. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate in human cancer xenografts.Biochem Pharmacol 1998; 55:1091-1093.
15. Hoff PM. Capecitabine as first-line treatment for colorectal cancer (CRC): integrated results of 1207 patients (pts) from 2 randomized, phase III studies. On behalf of the capecitabine CRC study group. Ann Oncol 2000; 11:60.
16. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001; 40:85-104.
17. Fraile RJ, Baker LH, Buroker TR, et al. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 1980; 40:2223-2228.
18. Heggie GD, Sommadoss JP, Gross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res 1987; 47:2203-2206.
19. Diasio RB, and Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16:215-237.
20. Ishikawa T, Utoh M, Sawada N, et al. Xeloda (capecitabine): an orally available tumor-sensitive fluoropyrimidine carbamate. Proc Am Soc Clin Oncol 1997; 16:208 (Abstract #796).
21. Cao S, Lu K, Ishitsuka H, Rustum YM. Antitumor efficacy of capecitabine against fluorouracil-sensitive and -resistant tumors. Proc Am Soc Clin Oncol 1997; 16:226 (Abstract #795).
22. Kawato Y, Aonuma M, Hirota Y, et al. Interacellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991; 51:4187-4191.
23. Wiseman LR, Markham A. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 1996; 52:606-623.
24. Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14:709-715.
25. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15:251-260.
26. Vanhoefer U, Harstrick A, Kohne CH, et al. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 1999; 17:907-913.
27. Cao S, Abraham A, Nair MG, et al. Polyglutamylation of dihydrofolate reductase inhibitor g-methylene-10-deaxaaminopterin is not essential for antitumor activity. Clin Cancer Res 1996; 2:707-712.
28. Cao S, McGuire JJ, Rustum YM. Antitumor activity of ZD1694 (Tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine. Clin Cancer Res 1999; 5:1925-1934.
29. Cao, S, Rustum YM. Synergistic Antitumor activity of Irinotecan in combination with 5-Fluorouracil in rats bearing advanced colorectal cancer: Role of drug sequence and dose. Cancer Res 2000; 60:3717-3721.
30. Azrak RG, Cao S, Slocum HK, et al. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res 2004; 10:1158-1167.
31. Cao S, Durrani FA, and Rustum YM. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 2004; 10:2561-2569.
32. Metzer R, Danenberg KD, Leichman CG, et al. High basal level gene expression of thymidine phosphorylase (plate-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998; 4:2371-2376.
33. Yin MB, Hapke G, Wu J, et al. Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350. Biochem Biophys Res Commun 2002; 295:435-444.
34. Yin MB, Guo B, Vanhoefer U, et al. Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol 2000; 57:453-459.
35. Kolfschoten GM, Hulscher TM, Pinedo HM, et al. Drug resistance features and S-phase fraction as possible determinants for drug response in a panel of human ovarian cancer xenografts. Br J Cancer 2000; 83:921-927.